PHASE I TRIAL OF SUNITINIB PLUS IMATINIB IN PATIENTS WITH METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)

被引：0
|
作者：
Lopez Pousa, A. [1 ]
Paz-Ares, L. [2 ]
Pericay, C. [3 ]
Garcia Del Muro, X. [4 ]
Flor, M. J. [5 ]
机构：
[1] Hosp Sta Creu & St Pau, Barcelona, Spain
[2] Hosp Virgen del Roc, Seville, Spain
[3] Corp Sanitaria Parc Tauli Inst Univ, Sabadell, Spain
[4] Inst Catala Oncol, Lhospitalet De Llobregat, Spain
[5] Hosp Virgen del Rocio, Oncol Serv, Seville, Spain
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：235 / 235
页数：1
相关论文
共 50 条
  • [41] Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors
    Lin Shen
    Yan Sun
    Jian-Ming Xu
    Carlos Linn
    Qiao Wang
    Li-Qiang Yang
    Shu-Kui Qin
    Oncology and Therapy, 2017, 5 (2) : 171 - 180
  • [42] Survival benefit of imatinib mesylate on patients with advanced gastrointestinal stromal tumors (GIST)
    Lin, M. T.
    Hu, T. H.
    Lin, J. W.
    Wang, C. C.
    Rau, K. M.
    Changchien, C. S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A44 - A44
  • [43] Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST)
    Casali, P. G.
    Joensuu, H.
    Broto, J. Martin
    del Muro, X. Garcia
    Blay, J.
    May, C.
    Pustowka, A.
    Reichardt, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate
    Rutkowski, P
    Nowecki, Z
    Nyckowski, P
    Dziewirski, W
    Grzesiakowska, U
    Nasierowska-Guttmejer, A
    Krawczyk, M
    Ruka, W
    JOURNAL OF SURGICAL ONCOLOGY, 2006, 93 (04) : 304 - 311
  • [45] Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
    Vincenzi, Bruno
    Nannini, Margherita
    Badalamenti, Giuseppe
    Grignani, Giovanni
    Fumagalli, Elena
    Gasperoni, Silvia
    D'Ambrosio, Lorenzo
    Incorvaia, Lorena
    Stellato, Marco
    Ceruso, Mariella Spalato
    Napolitano, Andrea
    Valeri, Sergio
    Santini, Daniele
    Tonini, Giuseppe
    Casali, Paolo Giovanni
    Dei Tos, Angelo Paolo
    Pantaleo, Maria Abbondanza
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [46] Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST)
    Campbell, N. P.
    Wroblewski, K.
    Maki, R. G.
    D'Adamo, D. R.
    Chow, W. A.
    Gandara, D. R.
    Antonescu, C.
    Stadler, W. M.
    Vokes, E. E.
    Kindler, H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [47] MECHANISMS OF IMATINIB-REISISTANCE IN GASTROINTESTINAL STROMAL TUMORS (GIST)
    Nishida, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 77 - 77
  • [48] Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
    Italiano, A.
    Cioffi, A.
    Maki, R. G.
    Schoffski, P.
    Rutkowski, P.
    Le Cesne, A.
    Duffaud, F.
    Adenis, A.
    Isambert, N.
    Bompas, E.
    Blay, J.
    Casali, P. G.
    Coco, P.
    D'Adamo, D. R.
    Keohan, M. L.
    Toulmonde, M.
    Antonescu, C.
    Debiec-Rychter, M.
    Coindre, J.
    Nguyen, B. Bui
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] Avapritinib for metastatic or unresectable gastrointestinal stromal tumors
    Alzofon, N.
    Jimeno, A.
    DRUGS OF TODAY, 2020, 56 (09) : 561 - 571
  • [50] Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus on Older Patients
    Dudzisz-Sledz, Monika
    Bylina, Elzbieta
    Teterycz, Pawel
    Rutkowski, Piotr
    DRUGS & AGING, 2021, 38 (05) : 375 - 396
12345